Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

AirSculpt Technologies, Inc.

$4.6

-0.14 (-2.95%)

Market Cap
368.25 M
EPS
-0.18
P/E Ratio
-29.51 $
Value Trade
4.48 M
SEC Financials
Q1 2026
  • Dilution Risk

    5%
  • Revenue

    39.39 M

  • Operating CF

    5.27 M


  • Total Assets

    192.00 M

  • Total Liabilities

    91.74 M

  • Equity

    100.26 M

  • D/E Ratio

    12,345

16.38 %
Week
113.2 %
1 Month
189.67 %
3 Month
44.84 %
6 Month
-58.49 %
5 Year
-58.49 %
All Time
Cash Data
Profitable
  • Cash Position

    16.69 M

  • Monthly Burn

    -

  • Runway

    12,345 mo

  • Burn Trend

    Stable
  • SEC Filing

    May 8, 2026
Overview
Volume
539.21 K
52 Week Range
1.51 - 12
% held by Insiders
90.43 %
% held by Institutions
22.94 %
Enterprise Value
424.18 M
Total Shares
70.43 M
Short %
21.81 %
Float Shares
16.97 M
Company Description
HQ: 1111 LINCOLN ROAD, MIAMI BEACH...
Founded:2012
Employees:363

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01
Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01
Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLD
INSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLD
HEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
AirSculpt Technologies, Inc. (AIRS) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
AIRS
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
AIRS
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
AIRS
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
AIRS Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
AIRS Institutional Ownership Trends
Current Insider %
5.20%
+0.00%
Current Institutional %
62.40%
+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
2026-07-17 0.00 0 - - - - - -
2026-07-17 0.00 0 - - - - - -
2026-07-17 0.00 0 - - - - - -
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
AIRS
May 8, 2026
AIRSGeneral

AirSculpt Technologies Reports First Quarter Fiscal 2026 Results Same Center Sales Increase 1% and Reaffirms Fiscal Year 2026 Outlook

AirSculpt Technologies announced its first quarter results for fiscal 2026, reporting a 1% increase in same center sales. The company achieved stabilization in revenue, holding flat at $39.4 million, and is reaffirming its full year guidance for revenue and adjusted EBITDA. Despite a net loss of $2.4 million, AirSculpt's performance reflects a solid foundation for future growth, with an optimistic outlook as they capitalize on enhanced marketing initiatives and operational strategies.

Read more →
AIRS
Apr 6, 2026
AIRSGeneral

AirSculpt Technologies Reports Fourth Quarter and Full Year Fiscal 2025 Results

AirSculpt Technologies, Inc. reported its fourth quarter and full year fiscal results for 2025, highlighting a decline in case volume and revenue compared to the previous year. Despite these challenges, the CEO noted improvements in same-store sales and the company's adaptation of new strategies and team enhancements. The firm projects a modest revenue growth for 2026, indicating a cautious optimism for recovery while facing increased competition and financial challenges.

Read more →
AIRS
Nov 17, 2025
AIRSGeneral

AirSculpt Technologies Appoints Mike Doyle as Non-Executive Chairman of the Board

AirSculpt Technologies has appointed Mike Doyle as the Non-Executive Chairman of the Board. Doyle, who has over 30 years of experience in the healthcare sector, is recognized for his leadership in multi-center healthcare organizations. His appointment is intended to support AirSculpt's next phase of transformation as the company seeks new opportunities in the market. CEO Yogi Jashnani expressed confidence in Doyle's ability to create value for stakeholders.

Read more →
AIRS
Nov 7, 2025
AIRSGeneral

AirSculpt Technologies Reports Third Quarter Fiscal 2025 Results

AirSculpt Technologies reported its third quarter fiscal 2025 results, noting a revenue decline of 17.8% to $35.0 million compared to the same quarter last year. Despite lower revenue and an increased net loss of $9.5 million, CEO Yogi Jashnani highlighted strong progress in growth initiatives and an improved outlook for same store sales. The company also successfully reduced its debt and remains focused on leveraging opportunities in the aesthetics market due to GLP-1 use. AirSculpt is set to update its full-year revenue guidance as it adjusts expectations for EBITDA.

Read more →
AIRS
Aug 1, 2025
AIRSGeneral

AirSculpt Technologies Reports Second Quarter Fiscal 2025 Results

AirSculpt Technologies reported its second quarter fiscal 2025 results, highlighting a 14.1% decline in case volume and a 13.7% drop in revenue year-over-year. Despite these declines, the company narrowed its losses and reported increased consumer consultations, signaling potential for future growth. CEO Yogi Jashnani mentioned the introduction of new services and affirmed the company's annual guidance. Additionally, CFO Dennis Dean announced his upcoming retirement but committed to ensuring a smooth transition.

Read more →
AIRS
Jun 9, 2025
AIRSGeneral

AirSculpt Announces Public Offering of Common Stock

AirSculpt Technologies, Inc. has announced a public offering of 3,160,000 shares of its common stock, with an option for the underwriter to purchase an additional 474,000 shares. The proceeds are intended for debt repayment and general corporate purposes. Vesey Street Capital Partners has shown interest in buying up to $4 million in shares, but commitments are not binding. The offering may face market condition uncertainties that could affect its completion and may lead to shareholder dilution.

Read more →
AIRS
May 2, 2025
AIRSGeneral

AirSculpt Technologies Reports First Quarter Fiscal 2025 Results and Full Year Guidance

AirSculpt Technologies, Inc. reported its first quarter fiscal 2025 results, highlighting a 17.9% decrease in case volume and a 17.3% decline in revenue. Despite these setbacks, CEO Yogi Jashnani expressed optimism about the company's new go-to-market strategy and ongoing cost reduction initiatives. The company anticipates improving revenue and EBITDA guidance for the full year 2025, projecting revenues between $160 and $170 million. AirSculpt believes in its long-term growth potential and plans to introduce new financing options and services to drive future performance.

Read more →
AIRS
Mar 14, 2025
AIRSGeneral

AirSculpt Technologies Reports Fourth Quarter, and Full Year Fiscal 2024 Results

AirSculpt Technologies announced its fourth quarter and full year results for fiscal 2024, highlighting challenges such as a decline in case volume and revenue. The company reported a net loss of $8.3 million for the year and $5.0 million for the fourth quarter. CEO Yogi Jashnani outlined plans to stabilize sales performance and improve operations in 2025, despite anticipating a tough first quarter due to reduced marketing activities. The company is implementing a cost reduction program to enhance liquidity as it aims for a more profitable future.

Read more →
AIRS
Jan 13, 2025
AIRSGeneral

AirSculpt Technologies Updates Fiscal Year 2024 Guidance in Advance of its Participation in the ICR Conference 2025

AirSculpt Technologies has updated its fiscal year 2024 guidance as it prepares to participate in the ICR Conference 2025. Newly appointed CEO Yogi Jashnani highlighted the company's potential for long-term growth through its proprietary technology and an asset-light business model. He emphasized the necessity of implementing operational changes and leveraging technology for improved decision-making. While optimistic about future performance, the company acknowledged potential risks associated with its guidance as it awaits year-end audits and results.

Read more →
AIRS
Dec 17, 2024
AIRSGeneral

AirSculpt Technologies Names Yogi Jashnani Chief Executive Officer

AirSculpt Technologies Inc. has appointed Yogi Jashnani as its new Chief Executive Officer, effective January 7, 2025, taking over from Dennis Dean, who will remain as Chief Financial Officer. Jashnani, with a proven track record in driving revenue growth in the aesthetics and retail industries, aims to enhance operational efficiencies and expand market opportunities for AirSculpt. The company's innovative body contouring technology and effective consumer strategies serve as a solid foundation for its future growth.

Read more →
AIRS
Nov 8, 2024
AIRSGeneral

AirSculpt Technologies Reports Third Quarter Fiscal 2024 Results Third Quarter Revenue of $42.5 million, Net Loss of $6.0 million and Adjusted EBITDA of $4.7 million

AirSculpt Technologies announced its third quarter fiscal 2024 results, reporting revenue of $42.5 million, down from $46.8 million in the same period last year, alongside a net loss of $6.0 million. Although the company opened four new centers and plans to maintain its revenue guidance for the year, challenges persist as case volume has declined by 4.3% from the previous year. The company aims to enhance lead conversions and improve margins while navigating ongoing market difficulties and potential risks tied to expansion and competition.

Read more →
AIRS
Oct 24, 2024
AIRSGeneral

Document AirSculpt Technologies Announces Preliminary Third Quarter 2024 Revenue Results Expects 2024 Revenue in the Range of $183 Million to $189 Million Announces Third Quarter Fiscal 2024 Earnings Date and Conference

AirSculpt Technologies announced preliminary financial results for the third quarter of 2024, projecting revenue of approximately $42.5 million, a 9% decrease compared to the prior year. Despite the decline, the company reported an improvement in same-store cases. AirSculpt also announced it expects full-year revenue in the range of $183 million to $189 million, slightly adjusted from earlier guidance. The company has plans to maintain its Adjusted EBITDA outlook and will conduct an earnings call on November 8, 2024.

Read more →
AIRS
Aug 9, 2024
AIRSGeneral

AirSculpt Technologies Reports Second Quarter Fiscal 2024 Results Second Quarter Revenue of $51.0 million, Net Loss of $3.2 million and Adjusted EBITDA of $6.9 million Company Revises 2024 Guidance

AirSculpt Technologies reported its second quarter fiscal 2024 results, highlighting a revenue of $51.0 million and a net loss of $3.2 million. The company's revenue dropped 8.4% compared to the previous year's second quarter, aligning with a challenging consumer spending environment. The new interim CEO, Dennis Dean, has expressed a focus on stabilizing revenue and reducing costs, with plans to open five new centers in the second half of 2024. Despite these challenges, AirSculpt noted positive performance in recently opened locations, indicating ongoing demand for their services.

Read more →
AIRS
Aug 9, 2024
AIRSGeneral

AirSculpt Technologies Announces Leadership Changes

AirSculpt Technologies, Inc. announced leadership changes with Todd Magazine stepping down as CEO, while Dennis Dean has been appointed as the interim CEO. The company aims to refocus on core operations and enhance fiscal discipline to drive future growth. Despite the leadership transition, there is optimism from the board regarding the potential for scale and profitability in the body contouring market. However, the company must navigate external economic challenges and competition to achieve its goals.

Read more →
AIRS
May 10, 2024
AIRSGeneral

AirSculpt Technologies Reports for First Quarter Earnings

AirSculpt Technologies reported positive first quarter results for 2024, with revenue increasing by 3.9% year-over-year and net income turning positive at $6.0 million. Despite this progress, the company faced challenges such as a decline in adjusted EBITDA and softness in same-store performance attributed to macroeconomic factors. AirSculpt plans to open six new centers later in the year, maintaining its guidance for overall revenue and adjusted EBITDA for 2024. The CEO expressed confidence in future growth fueled by newly opened locations and customer acquisition efforts.

Read more →
AIRS
Feb 27, 2024
AIRSGeneral

AirSculpt Technologies Reports Double Digit Revenue Growth for the Fourth Quarter and Full Year 2023

AirSculpt Technologies reported strong financial results for Q4 and the full year 2023, with a 17% increase in revenue to $47.6 million in Q4 and a total revenue of $195.9 million for the year, up 16.1% year-over-year. The company also improved its net loss to $4.5 million for the year, compared to a loss of $14.7 million in 2022. Adjusted EBITDA showed significant growth, rising 27.9% in Q4 to $10.1 million. Looking ahead, AirSculpt projects approximately $220 million in revenue and $50 million in adjusted EBITDA for 2024, with plans to open six new centers in the second half of the year.

Read more →
AIRS
Nov 9, 2023
AIRSGeneral

AirSculpt Technologies Announces Third Quarter 2023 Results and Reaffirms 2023 Guidance

AirSculpt Technologies reported a strong performance for the third quarter of 2023, with case volume up 19% and revenue increasing by 20.3% year-over-year. The company achieved a net loss of $(1.7) million, an improvement from the previous year's loss of $(7.4) million. AirSculpt reaffirmed its guidance for 2023, anticipating revenues of approximately $196 million and at least $45 million in adjusted EBITDA. This positive momentum is attributed to successful operations in newly opened centers and growing demand for their body contouring procedures.

Read more →
AIRS
Oct 5, 2023
AIRSGeneral

Document AirSculpt Technologies Announces Strong Preliminary Third Quarter 2023 Revenue Results and Updates 2023 Revenue and Adjusted EBITDA Guidance

AirSculpt Technologies reported strong preliminary financial results for Q3 2023, projecting revenue of approximately $46.5 million, a 20% increase compared to the previous year. The company also updated its total revenue guidance for 2023, now expecting around $196 million, up from its earlier forecast. Additionally, the adjusted EBITDA guidance was raised to at least $45 million. The positive outcomes reflect strong same-store revenue growth and contributions from new centers while also indicating ongoing efforts to strengthen its balance sheet.

Read more →
AIRS
Aug 11, 2023
AIRSGeneral

AirSculpt Technologies Announces Second Quarter 2023 Results and Reaffirms 2023 Guidance

AirSculpt Technologies reported their second quarter results for 2023, showcasing a revenue increase of 12.2% to $55.7 million, alongside a net income jump to $1.8 million. The company saw a 13.4% rise in case volume, totaling 4,186 procedures. Furthermore, AirSculpt reaffirmed its full-year guidance, predicting revenues between $187 to $192 million and adjusted EBITDA of $43 to $45 million. The company continues to expand its footprint with the opening of new centers, including a recent location in London.

Read more →
AIRS
Jul 11, 2023
AIRSGeneral

AirSculpt Technologies Announces Strong Preliminary Second Quarter 2023 Revenue, Reaffirms 2023 Revenue Guidance and Updates 2023 Adjusted EBITDA Guidance

AirSculpt Technologies announced a strong preliminary revenue estimate of approximately $55.7 million for Q2 2023, reflecting a 12.2% increase from the previous year. The company reaffirmed its 2023 revenue guidance and plans to open five new centers, three of which have already opened successfully. However, the Adjusted EBITDA outlook has been revised down to a range of $43 to $45 million due to changes in reporting adjustments despite maintaining operational confidence. Overall, the company is emphasizing growth and expansion while acknowledging potential risks that could impact future performance.

Read more →
AIRS
May 12, 2023
AIRSGeneral

AirSculpt Technologies Announces First Quarter 2023 Results, Reaffirms 2023 Guidance and Announces London Opening

AirSculpt Technologies reported a strong performance for Q1 2023, with a 15.3% increase in case volume and a revenue boost of 15.9% to $45.8 million. The company's net loss reduced significantly compared to the previous year, ending with a loss of just $14 thousand. AirSculpt also discussed its plans for future growth, including the opening of new centers and maintaining its revenue and EBITDA guidance for the year. Additionally, the approval for a flagship center in London signifies potential expansion opportunities.

Read more →
AIRS
Mar 10, 2023
AIRSGeneral

AirSculpt Technologies Announces Fourth Quarter 2022 Results and Provides 2023 Guidance

AirSculpt Technologies, Inc. reported a successful fourth quarter for 2022 with a 15.7% increase in case volume and an 8.4% rise in revenue compared to the previous year. The company also provided optimistic guidance for 2023, projecting revenues between $187 to $192 million and plans to open five new centers. Despite these positives, the company reported a diluted loss per share and increased operating expenses that affected profitability. AirSculpt continues to expand its operations and management team in anticipation of further growth.

Read more →
AIRS
Jan 6, 2023
AIRSGeneral

AirSculpt Technologies, Inc. Announces Executive Leadership Changes & Reiterates 2022 Revenue Guidance Todd Magazine Appointed CEO & Dr. Aaron Rollins Named Executive Chairman Miami Beach, Fla.

AirSculpt Technologies, Inc. announced significant executive leadership changes, appointing Todd Magazine as the new CEO while Founder Dr. Aaron Rollins transitions to Executive Chairman. This strategic shift is aimed at enhancing the company's growth strategy in the body contouring market. The company also confirmed its revenue guidance for 2022, projecting earnings between $168-$170 million. Magazine, with over 30 years of industry experience, aims to leverage AirSculpt's proprietary technology to drive brand awareness and increase market growth.

Read more →
AIRS
Nov 10, 2022
AIRSGeneral

AirSculpt Technologies, Inc. Announces Third Quarter 2022 Results

AirSculpt Technologies, Inc. Announces Third Quarter 2022 Results MIAMI BEACH, Fla., November 10, 2022 (GLOBE NEWSWIRE) - AirSculpt Technologies, Inc. (NASDAQ AIRS)("AirSculpt" or the "Company"), a national provider of premium body contouring procedures, today announced results

Read more →
AIRS
Aug 12, 2022
AIRSGeneral

AirSculpt Technologies, Inc. Announces Second Quarter 2022 Results and Authorizes Special Cash Dividend

AirSculpt Technologies, Inc. Announces Second Quarter 2022 Results and Authorizes Special Cash Dividend MIAMI BEACH, Fla., August 12, 2022 (GLOBE NEWSWIRE) - AirSculpt Technologies, Inc. (NASDAQ AIRS)("AirSculpt" or the "Company"), a national provider of premium body contouring

Read more →
AIRS
May 13, 2022
AIRSGeneral

AirSculpt Technologies, Inc. Announces First Quarter 2022 Results

AirSculpt Technologies, Inc. Announces First Quarter 2022 Results MIAMI BEACH, Fla., May 13, 2022 (GLOBE NEWSWIRE) - AirSculpt Technologies, Inc. (NASDAQ AIRS)("AirSculpt" or the "Company"), a national provider of premium body contouring procedures, today announced results for t

Read more →
AIRS
Mar 11, 2022
AIRSGeneral

AirSculpt Technologies, Inc. Announces Fourth Quarter and Full Year 2021 Results

AirSculpt Technologies, Inc. Announces Fourth Quarter and Full Year 2021 Results MIAMI BEACH, Fla., March 11, 2022 (GLOBE NEWSWIRE) - AirSculpt Technologies, Inc. (NASDAQ AIRS)("AirSculpt" or the "Company"), a national provider of premium body contouring procedures, today announ

Read more →
AIRS
Dec 3, 2021
AIRSGeneral

AirSculpt Technologies, Inc. Announces Third Quarter 2021 Results

AirSculpt Technologies, Inc. Announces Third Quarter 2021 Results MIAMI BEACH, Fla., December 3, 2021 (GLOBE NEWSWIRE) - AirSculpt Technologies, Inc. (NASDAQ:AIRS)("AirSculpt" or the "Company"), a national provider of premium body contouring procedures, today announced result

Read more →
Competitive Position
How AIRS ranks across every disease it competes in
Competitive Position is a premium feature
See how AIRS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial